Page 2 of 212

Antibiotics Risky for Nifedipine Users: Study Antiobiotics save lives.

Said Juurlink, It is the right move to make. .. Antibiotics Risky for Nifedipine Users: Study Antiobiotics save lives, but they also pose risks – including some that doctors may fail to recognize. Case in point: The favorite antibiotics erythromycin and clarithromycin can trigger dangerously low blood circulation pressure when taken by individuals who currently take nifedipine or another so-called calcium-channel blocker. That is the key finding of a fresh study published in the Canadian Medical Association Journal. Continue reading

Produced by Australian biotechnology firm.

We have been very excited about numerous features of the medication. It includes a dual setting of action, straight killing tumor cells and at the same time starving the malignancy of its blood circulation. Cancers depend on this blood source for their development, he stated. Dr Healey stated the drug appeared as if it will be effective when used orally which will be a major advantage for patients. Furthermore, CYT997 seems to avoid a few of the mechanisms that enable tumours to be resistant to existing first series drugs, he stated. Cytopia’s Chief Scientific Officer, Dr Andrew Wilks stated that the Stage I study will be a non-blinded, dosage escalation study in sufferers with numerous cancers and could consider between nine and a year. Continue reading

S BioScience business.

Baxter International acquires medication candidate developed to take care of sickle cell disease Potential treatment targets sickle cell disease A drug candidate produced by researchers at the NIH's National Middle for Advancing Translational Sciences and its own collaborators to take care of sickle cell disease has been acquired by Baxter International's BioScience business how good is generic cialis . The drug applicant, Aes-103, may be the first particularly developed to focus on the underlying molecular system of sickle cell disease. Baxter now will progress the clinical development actions necessary for regulatory commercialization and acceptance. Continue reading

Canadian cardiologists.

‘We tested 14 of the 18 patients who were place back on herceptin and they were all able to complete the treatment,’ Dr. McDonald told the conference. The million dollar question is: does herceptin cause long lasting damage to the heart? With the development of newer cancer medicines that act in an identical fashion to herceptin, understanding the effect of this therapy upon the cardiovascular response and system to intervention is definitely critically important. ‘It needs cross-specialty teamwork but coping with herceptin-related cardiac problems is a challenge that can be fulfilled,’ says Dr. McDonald. Stroke and Center Foundation spokesperson Dr. Beth Abramson agrees: ‘That is very good news for Canadian women,’ she says. Continue reading

Page 2 of 212